The US FDA Approves Eli Lilly’s Jaypirca (Pirtobrutinib) for Certain Patients with Previously Untreated CLL/SLL

Shots: The US FDA has approved an additional indication for Jaypirca (pirtobrutinib, 100 & 50mg) for the treatment of adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion Approval was based on the P-III (BRUIN CLL-313) trial data P-III assessing Jaypirca (200mg, PO, QD until disease progression…

ByRidhi Rastogi3 days ago

NEWS

Eli Lilly Reports P-III (TRIUMPH-2) Results on Retatrutide for Obesity and Type 2 Diabetes

Shots: TRIUMPH-2 assessed retatrutide (4, 9, or 12mg, QW) vs PBO in 1152 pts with T2D & obesity/overweight, with trial using a stepwise dose-escalation approach at Q4W. Lilly plans to file BLA in Q1’27 At 80wks., avg. body weight reductions were 12.7% (4mg), 19.1% (9mg), & 20.8% (12mg) vs 4%, plus A1C reduced by 1.4%,…

ByRidhi RastogiSeptember 30, 2026

NEWS

Eli Lilly Reports the US FDA Approval for Olumiant to Treat Severe Alopecia Areata in Pediatric Patients

Shots: The US FDA has approved Olumiant (baricitinib) for the treatment of pediatric pts (≥12yrs.) with severe alopecia areata (AA), expanding its use from treating adults with mod. to sev. active rheumatoid arthritis & sev. AA Approval was based on 36wk. data from the adolescent cohort (12 to <18yrs.) of P-III (BRAVE-AA-PEDS) study assessing Olumiant…

ByRidhi RastogiSeptember 28, 2026

NEWS

Eli Lilly Reports the US FDA Approval for Onswik to Treat Type 2 Diabetes

Shots: The US FDA has approved Onswik (insulin efsitora alfa-gobe) along with diet and exercise to control high blood sugar in adults with type 2 diabetes Approval was based on the P-III (QWINT) trials, which evaluated Onswik (QW) in >3,400 adults with T2D; across each trial, Onswik met the 1EP, demonstrating non-inferior A1C reductions vs…

ByRidhi RastogiSeptember 25, 2026

NEWS

InnoCare Partners with Eli Lilly in a ~$3.35B Drug Development Deal

Shots: InnoCare has entered into a strategic research collaboration & license agreement with Eli Lilly to develop new medicines, using its drug discovery platform As per the deal, InnoCare will leverage its drug discovery platform & research expertise to discover & advance compounds against up to five targets addressing critical unmet medical needs InnoCare will…

ByRidhi RastogiSeptember 24, 2026

NEWS

Eli Lilly Receives Full FDA Approval for Inluriyo + Verzenio to Treat ESR1-mutated Breast Cancer

Shots: FDA has granted full approval to Inluriyo (imlunestrant; PO) + Verzenio (abemaciclib) for treating adults with ER+, HER2-, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after ≥1L of endocrine therapy (ET) Approval was based on the P-III (EMBER-3) trial assessing Inluriyo ± Verzenio in ESR1-mutated MBC pts (n=159); Inluriyo + Verzenio (n=67) doubled the…

ByRidhi RastogiSeptember 21, 2026

NEWS

QurCan Therapeutics Partners with Eli Lilly to Develop Nucleic Acid Therapies for CNS and PNS Diseases

Shots: QurCan Therapeutics has entered into an exclusive research & collaboration agreement with Eli Lilly for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS) Lilly & QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicines for CNS & PNS delivery, with QurCan…

ByRidhi RastogiSeptember 15, 2026

NEWS

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

Shots: OmniAb has entered a global collaboration & license agreement with Eli Lilly for a new ion channel program, leveraging OmniAb’s discovery & screening platform to identify next-generation therapeutics targeting ion channels The therapeutic target and modality remain undisclosed, while OmniAb will contribute its established expertise and technology in ion channel discovery & screening As…

ByRidhi RastogiAugust 17, 2026

TOP 20

Top 20 R&D Spending Biopharma Companies of 2026

Shots: Merck & Co., Roche, and Johnson & Johnson emerged as the leading pharmaceutical companies by R&D expenditure in 2025, investing $15.78B, $15.49B, and $14.66B, respectively. Continued investments in late-stage clinical programs, pipeline expansion, advanced technologies, and strategic business development reinforced their commitment to driving pharmaceutical innovation Global biopharmaceutical R&D investment continues to accelerate as…

ByPrince GiriJuly 31, 2026

NEWS

Eli Lilly Reports P-III (TRIUMPH-2 and TRIUMPH-3) Results on Retatrutide for Obesity

Shots: TRIUMPH-2 assessed retatrutide (4, 9, or 12mg, QW) vs PBO in 1152 pts with T2D & obesity/overweight, while TRIUMPH-3 assessed retatrutide (9 or 12mg, QW) in 1949 pts with severe obesity & CV disease; trials used a stepwise dose-escalation approach at Q4W In TRIUMPH-3, 12mg reduced TGs, non-HDL cholesterol, systolic BP, waist circumference, &…

ByRidhi RastogiJuly 24, 2026

The US FDA Approves Eli Lilly’s Jaypirca (Pirtobrutinib) for Certain Patients with Previously Untreated CLL/SLL

Eli Lilly Reports P-III (TRIUMPH-2) Results on Retatrutide for Obesity and Type 2 Diabetes

Eli Lilly Reports the US FDA Approval for Olumiant to Treat Severe Alopecia Areata in Pediatric Patients

Eli Lilly Reports the US FDA Approval for Onswik to Treat Type 2 Diabetes

InnoCare Partners with Eli Lilly in a ~$3.35B Drug Development Deal

Eli Lilly Receives Full FDA Approval for Inluriyo + Verzenio to Treat ESR1-mutated Breast Cancer

QurCan Therapeutics Partners with Eli Lilly to Develop Nucleic Acid Therapies for CNS and PNS Diseases

OmniAb and Eli Lilly Partner on New Ion Channel Discovery Program

Top 20 R&D Spending Biopharma Companies of 2026

Eli Lilly Reports P-III (TRIUMPH-2 and TRIUMPH-3) Results on Retatrutide for Obesity

Contact US

FOLLOW US